TARA Protara Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: TARA

Price (delayed)

$4.45

Market cap

$250.11M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.35

Enterprise value

$238.43M

?
Relative Growth: Rel. Growth: 9
Relative Strength: Rel. Strength: 32
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 5

Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options. Protara's portfolio includes its lead program, TARA-002, an investigational cell-based ...

Highlights
The debt has decreased by 28% YoY and by 9% from the previous quarter
The EPS has increased by 19% year-on-year
The equity rose by 14% year-on-year but it has declined by 8% since the previous quarter
Protara Therapeutics's quick ratio has decreased by 14% YoY but it has increased by 7% from the previous quarter
The company's net income fell by 39% YoY and by 10% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://protaratx.com/
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of TARA

TARA stock price

How has the Protara Therapeutics stock price performed over time
Intraday
5.45%
1 week
-6.32%
1 month
-18.35%
1 year
38.2%
YTD
-16.51%
QTD
-14.59%

Financial performance

How have Protara Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$70.05M
Net income
-$63.31M
Gross margin
N/A
Net margin
N/A
The company's net income fell by 39% YoY and by 10% QoQ
TARA's operating income is down by 36% year-on-year and by 9% since the previous quarter

Price vs fundamentals

How does TARA's price correlate with its fundamentals

Growth

What is Protara Therapeutics's growth rate over time

Valuation

What is Protara Therapeutics stock price valuation
P/E
N/A
P/B
1.33
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has increased by 19% year-on-year
TARA's P/B is 110% above its 5-year quarterly average of 0.6 and 5% above its last 4 quarters average of 1.2
The equity rose by 14% year-on-year but it has declined by 8% since the previous quarter

Efficiency

How efficient is Protara Therapeutics business performance
TARA's return on invested capital has surged by 67% year-on-year and by 9% since the previous quarter
The ROA has contracted by 8% YoY and by 7% from the previous quarter
TARA's ROE is down by 6% since the previous quarter and by 6% year-on-year

Dividends

What is TARA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TARA.

Financial health

How did Protara Therapeutics financials performed over time
The total liabilities is down by 18% since the previous quarter but it is up by 6% year-on-year
The total assets has increased by 14% year-on-year but it has declined by 8% since the previous quarter
The debt is 98% less than the equity
Protara Therapeutics's debt to equity has decreased by 33% YoY
The debt has decreased by 28% YoY and by 9% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.